Half-life
Community practice: split doses morning and evening for GlyNAC given the ~6 hour plasma half-life of NAC
Evidence
CAnimal replicated
The Oral Bioavailability Problem
Standard oral glutathione has bioavailability below 1% due to cleavage by gamma-glutamyltransferase (GGT) and other GI enzymes in the gut lumen and intestinal brush border. The tripeptide is cleaved to its constituent amino acids before systemic absorption. The body then uses these as building blocks for endogenous synthesis — which it would have done anyway from dietary amino acids. Standard oral supplementation does not meaningfully raise systemic GSH in most healthy individuals. Allen et al. (1992): no significant change in blood GSH with 500 mg twice daily for 4 weeks. High-dose (3g) oral supplementation: similarly unimpressive results.
Liposomal and Micellar Forms
Liposomal encapsulation (e.g., Setria® Liposomal) and micellar delivery (e.g., LipoMicel®) protect GSH from GI degradation in a lipid envelope, improving bioavailability over standard oral. A 2026 crossover RCT (Antioxidants, n=14): both liposomal and micellar formulations significantly increased whole-blood GSH vs standard oral, with the micellar formulation producing greater incremental exposure. 'Significantly better' than standard oral is a low bar — standard oral barely works. Absolute increases in circulating GSH from oral liposomal are modest. The clinical meaningfulness of these increases has not been established in outcome trials.
IV Glutathione — 100% Bioavailability, Real Safety Risks
Intravenous GSH bypasses GI degradation entirely, achieving 100% bioavailability and rapid tissue distribution. Legitimate medical uses: adjunct in cisplatin chemotherapy to reduce neuropathy; severe liver disease support in some protocols. SAFETY CONCERN: the US FDA issued a formal advisory in 2019 citing adverse events from compounded injectable glutathione — 7 patients in one clinic, symptoms within minutes including nausea, vomiting, hypotension, difficulty breathing requiring hospitalization. The Philippine FDA (2019) issued a public warning against IV glutathione for skin lightening. A 39-year-old woman died in the Philippines in 2024 following IV glutathione + stem cell treatment. 2025 systematic review: IV glutathione contraindicated for cosmetic use due to anaphylaxis, hepatotoxicity, and SIRS risk.
The GlyNAC Strategy — The Alternative That Outperforms Direct Supplementation
Because oral GSH cannot meaningfully raise intracellular levels, the most evidence-supported approach to raising cellular glutathione is supplying the rate-limiting precursors for endogenous synthesis. Cysteine (the rate-limiting amino acid) is provided as NAC (N-acetylcysteine); glycine is provided directly. Together this is GlyNAC. Sekhar RV (Baylor/Houston Methodist) — multiple RCTs: GlyNAC supplementation in older adults corrected GSH deficiency, improved mitochondrial function, reduced oxidative stress markers (TBARS -80%), reduced inflammation (IL-6 -83%), reduced insulin resistance (HOMA-IR -68%), improved gait speed and physical function. Grade B human evidence. The indirect approach — feed the synthesis pathway — appears more effective than supplementing the end product.
Skin Brightening/Whitening Evidence
Tyrosinase inhibition by GSH shifts melanin synthesis from eumelanin (dark) toward pheomelanin (light) — the biological basis for the pigmentation effect. ORAL: 5 RCTs showing significant reduction in melanin index at 250-500 mg/day (Sarkar 2025 systematic review). Effect is real but inconsistent across studies, not permanent (requires ongoing use), and produces generalized rather than localized effects. TOPICAL: moderate evidence; Wahab 2021 RDBPC (n=46) showed combination oral + topical superior to monotherapy. IV: only 1 placebo-controlled trial; Sarkar 2025 review concluded IV glutathione is contraindicated due to safety concerns and lack of efficacy evidence for cosmetic use.
The 'Detox' Claim — Real Mechanism, Overclaimed Application
Glutathione S-transferases (GSTs) in the liver catalyze conjugation of GSH to reactive electrophilic compounds — Phase II detoxification. This is real, well-established biochemistry. The community claim that GSH supplementation 'detoxifies' the body or 'removes toxins' extrapolates mechanistic biology into a clinical application that has not been established. The body's GSH production for hepatic detoxification is primarily endogenous and regulated; it is not routinely limited by substrate supply in healthy adults. GSH supplementation does not produce measurably increased 'detox' capacity in healthy individuals with normal GSH levels.
Forms Available
Reduced L-Glutathione (standard): oral; cheapest; minimal efficacy for raising systemic levels. Liposomal GSH (Setria® and others): oral; improved but still modest bioavailability. Micellar GSH (LipoMicel®): oral; best oral bioavailability in current evidence. S-Acetyl Glutathione: oral; acetyl group protects from GI degradation; some bioavailability data. Sublingual: limited evidence; faster onset than oral if absorbed buccally. IV: 100% bioavailable; medical setting only; real safety concerns. Nebulized: inhaled for pulmonary applications; bronchospasm risk (especially asthma). Topical: skin delivery; local effect; no meaningful systemic levels.
WADA Status
Not listed on the 2026 WADA Prohibited List.